Baird Maintains Outperform on Medpace Hldgs, Lowers Price Target to $413
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Eric Coldwell maintains an Outperform rating on Medpace Holdings (NASDAQ:MEDP) but lowers the price target from $430 to $413.
September 20, 2024 | 11:23 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Baird analyst Eric Coldwell maintains an Outperform rating on Medpace Holdings but lowers the price target from $430 to $413.
The Outperform rating suggests continued positive sentiment towards Medpace Holdings, but the lowered price target indicates a slight reduction in expected upside. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100